# Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission

> **NCT05596097** · PHASE2 · NOT_YET_RECRUITING · sponsor: **LanZhou University** · enrollment: 15 (estimated)

## Conditions studied

- Diffuse Large B-cell Lymphoma (DLBCL)

## Interventions

- **DRUG:** Zanubrutinib

## Key facts

- **NCT ID:** NCT05596097
- **Lead sponsor:** LanZhou University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-10-30
- **Primary completion:** 2024-10-20
- **Final completion:** 2026-07-30
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2022-10-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05596097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05596097, "Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05596097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*